CAS No.70-51-9,Deferoxamine Suppliers

Products Categories

Pharmaceutical (42)
Organic Chemicals (13)
Others (7)
Reagent (1)
Agrochemicals (1)
Catalyst and Auxiliary (1)
Materials (1)

Basic Information

Molecular Structure:
CAS No.:	70-51-9
Name:	Deferoxamine
Article Data:	10

Formula:	C25H48 N6 O8
Molecular Weight:	560.692
Synonyms:	Butanediamide,N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-(9CI); Propionohydroxamic acid,N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]-(8CI); 3,9,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone,30-amino-3,14,25-trihydroxy-; 30-Amino-3,14,25-trihydroxy-3,9,14,20,25pentaazatriacontane-2,10,13,21,24-pentaone; Deferoxamin; Deferoxamine;Deferoxamine B; Deferriferrioxamine B; Deferrioxamine; Deferrioxamine B;Desferan; Desferex; Desferin; Desferioxamine B; Desferrin; Desferrioxamine;Desferrioxamine B;N-[5-[3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]propionohydroxamicacid; NSC 527604
EINECS:	200-738-5
Density:	1.212g/cm3
Melting Point:	139°C
Boiling Point:	627.9°C (rough estimate)
Safety:	Poison by intravenous route. Moderately toxic by ingestion, intraperitoneal and subcutaneous routes. Human systemic effects: changes in hearing acuity, eye hemorrhage, optic nerve neuropathy, thrombocytopenia, visual field changes. Human mutation data reported. When heated to decomposition it emits toxic fumes of NO_x.
PSA:	205.84000
LogP:	2.40420

Synthetic route

: C46H64N8O8

: 70-51-9
deferoxamine

Conditions

Conditions	Yield
With palladium 10% on activated carbon; hydrogen; acetic acid In methanol at 25℃; under 760.051 Torr; for 0.333333h;	50%

: 402913-84-2
1-Carbobenzoxyamino-6,17-dihydroxy-7,10,18,21-tetraoxy-27-(N-acetyl-hydroxyamino)-6,11,17,22-tetraaza-hepteikosan

: 70-51-9
deferoxamine

Conditions

Conditions	Yield
With hydrogenchloride; hydrogen; palladium on activated charcoal In methanol

: 112139-65-8
N'-<5-<<4-<<5-pentyl>amino>-1,4-dioxobutyl>(phenylmethoxy)amino>pentyl>-N-(4-cyanobutyl)-N-(phenylmethoxy)butanediamide

: 70-51-9
deferoxamine

Conditions

Conditions	Yield
With hydrogenchloride; hydrogen; palladium on activated charcoal In methanol

: 129245-21-2
N-(5-aminopentyl)-N-(tert-butoxycarbonyl)-O-benzylhydroxylamine

: 70-51-9
deferoxamine

Conditions

Conditions	Yield
Multi-step reaction with 7 steps 1: 99 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C 2: 87 percent / trifluoroacetic acid (TFA) / CH2Cl2 / 0.75 h / 0 - 20 °C 3: 96 percent / pyridine 4: 95 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C 5: 100 percent / trifluoroacetic acid (TFA) / CH2Cl2 6: 91 percent / pyridine / 12 h 7: H2, HCl / 10percent Pd/C / methanol View Scheme

Yield

Multi-step reaction with 7 steps
1: 99 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C
2: 87 percent / trifluoroacetic acid (TFA) / CH2Cl2 / 0.75 h / 0 - 20 °C
3: 96 percent / pyridine
4: 95 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C
5: 100 percent / trifluoroacetic acid (TFA) / CH2Cl2
6: 91 percent / pyridine / 12 h
7: H2, HCl / 10percent Pd/C / methanol
View Scheme

: 129245-24-5
5,16-bis(benzyloxy)-20-cyano-4,12,15-trioxo-5,11,16-triazaeicosanoic acid

: 70-51-9
deferoxamine

Conditions

Conditions	Yield
Multi-step reaction with 4 steps 1: 95 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C 2: 100 percent / trifluoroacetic acid (TFA) / CH2Cl2 3: 91 percent / pyridine / 12 h 4: H2, HCl / 10percent Pd/C / methanol View Scheme

: 130946-41-7
27--6,17-bis(benzyloxy)-7,10,18,21-tetraoxo-6,11,17,22-tetraazaheptacosanenitrile

: 70-51-9
deferoxamine

Conditions

Conditions	Yield
Multi-step reaction with 2 steps 1: 91 percent / pyridine / 12 h 2: H2, HCl / 10percent Pd/C / methanol View Scheme

: 130946-40-6
27--6,17-bis(benzyloxy)-7,10,18,21-tetraoxo-6,11,17,22-tetraazaheptacosanenitrile

: 70-51-9
deferoxamine

Conditions

Conditions	Yield
Multi-step reaction with 3 steps 1: 100 percent / trifluoroacetic acid (TFA) / CH2Cl2 2: 91 percent / pyridine / 12 h 3: H2, HCl / 10percent Pd/C / methanol View Scheme

: 112139-60-3
N-(4-Cyanobutyl)-N-(benzyloxy)succinamic Acid

: 70-51-9
deferoxamine

Conditions

Conditions	Yield
Multi-step reaction with 7 steps 1: 99 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C 2: 87 percent / trifluoroacetic acid (TFA) / CH2Cl2 / 0.75 h / 0 - 20 °C 3: 96 percent / pyridine 4: 95 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C 5: 100 percent / trifluoroacetic acid (TFA) / CH2Cl2 6: 91 percent / pyridine / 12 h 7: H2, HCl / 10percent Pd/C / methanol View Scheme

Yield

: 129245-23-4
N-(4-cyanobutyl)-3-<<5-<(benzyloxy)amino>pentyl>carbamoyl>-O-benzylpropionohydroxamic acid

: 70-51-9
deferoxamine

Conditions

Conditions	Yield
Multi-step reaction with 5 steps 1: 96 percent / pyridine 2: 95 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C 3: 100 percent / trifluoroacetic acid (TFA) / CH2Cl2 4: 91 percent / pyridine / 12 h 5: H2, HCl / 10percent Pd/C / methanol View Scheme

: 129245-22-3
N-(4-cyanobutyl)-3-<<5-<(benzyloxy)-tert-butoxy-carbonylamino>pentyl>carbamoyl>-O-benzylpropionohydroxamic acid

: 70-51-9
deferoxamine

Conditions

Conditions	Yield
Multi-step reaction with 6 steps 1: 87 percent / trifluoroacetic acid (TFA) / CH2Cl2 / 0.75 h / 0 - 20 °C 2: 96 percent / pyridine 3: 95 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C 4: 100 percent / trifluoroacetic acid (TFA) / CH2Cl2 5: 91 percent / pyridine / 12 h 6: H2, HCl / 10percent Pd/C / methanol View Scheme

Country:
Business Type:
All

Lab/Research institutions

Trading Company

Manufacturers

Other
Certificate:
Manufacturer

Enterprise Authentication

ISO

GMP

FDA

HALAL

Display:default sort
Suppiers of more reward points first

New supplier

Total:58 Page 1 of 2 1 2 Next>>

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 70-51-9

Chemistry

Molecular Formula: C₂₅H₄₈N₆O₈
Molar mass: 560.684 g/mol
EINECS: 200-738-5
Density: 1.212 g/cm³
Index of Refraction: 1.537
Structure of Deferoxamine (CAS NO.70-51-9):

Uses

Deferoxamine (CAS NO.70-51-9) is used to treat acute iron poisoning, especially in small children and is also frequently used to treat hemochromatosis, a disease of iron accumulation that can be either genetic or acquired. Another, it has also been used in the treatment of a patient with aceruloplasminemia.

Toxicity Data With Reference

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
child	TDLo	multiple routes	440mg/kg/6D-I (440mg/kg)	SENSE ORGANS AND SPECIAL SENSES: "RETINAL CHANGES (PIGMENTARY DEPOSITIONS, RETINITIS, OTHER): EYE"	Archives of Disease in Childhood. Vol. 63, Pg. 250, 1988.
child	TDLo	subcutaneous	12gm/kg/17W-I (12000mg/kg)	SENSE ORGANS AND SPECIAL SENSES: OPTIC NERVE NEUROPATHY: EYE SENSE ORGANS AND SPECIAL SENSES: CHANGE IN ACUITY: EAR	New England Journal of Medicine. Vol. 314, Pg. 869, 1986.
human	TDLo	subcutaneous	37gm/kg/2Y-I (37000mg/kg)	SENSE ORGANS AND SPECIAL SENSES: OPTIC NERVE NEUROPATHY: EYE	New England Journal of Medicine. Vol. 314, Pg. 869, 1986.
man	TDLo	intravenous	86mg/kg/1H-C (86mg/kg)	BLOOD: THROMBOCYTOPENIA	American Journal of Kidney Diseases. Vol. 6, Pg. 254, 1985.
mouse	LD50	intraperitoneal	1680mg/kg (1680mg/kg)		Kiso to Rinsho. Clinical Report. Vol. 4, Pg. 99, 1970.
mouse	LD50	intravenous	250mg/kg (250mg/kg)	LUNGS, THORAX, OR RESPIRATION: DYSPNEA	United States Patent Document. Vol. #4863964,
mouse	LD50	oral	1340mg/kg (1340mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 17, Pg. 748, 1967.
mouse	LD50	subcutaneous	1450mg/kg (1450mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 6, Pg. 119, 1975.
rat	LD50	intravenous	329mg/kg (329mg/kg)		Toxicology and Applied Pharmacology. Vol. 18, Pg. 185, 1971.
rat	LD50	subcutaneous	12240mg/kg (12240mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 6, Pg. 119, 1975.
women	TDLo	intravenous	40mg/kg (40mg/kg)	SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE SENSE ORGANS AND SPECIAL SENSES: HEMORRHAGE: EYE	Nephron. Vol. 46, Pg. 211, 1987.

Safety Profile

Poison by intravenous route. Moderately toxic by ingestion, intraperitoneal and subcutaneous routes. Human systemic effects: changes in hearing acuity, eye hemorrhage, optic nerve neuropathy, thrombocytopenia, visual field changes. Human mutation data reported. When heated to decomposition it emits toxic fumes of NO_x.

Specification

Deferoxamine ,its cas register number is 70-51-9. It also can be called Desferrioxamine B ; Desferoxamine B ; DFO-B ; DFOA ; DFB or Desferal . It acts by binding free iron in the bloodstream and enhancing its elimination in the urine. Deferoxamine (CAS NO.70-51-9) may modulate expression and release of inflammatory mediators by specific cell types. A recent study shows that it speeds healing of nerve damage. Its administration after acute intoxication may color the urine a pinkish red, a phenomenon termed "vin rose urine".